全文获取类型
收费全文 | 902篇 |
免费 | 43篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 18篇 |
妇产科学 | 3篇 |
基础医学 | 51篇 |
口腔科学 | 8篇 |
临床医学 | 40篇 |
内科学 | 271篇 |
皮肤病学 | 26篇 |
神经病学 | 270篇 |
特种医学 | 35篇 |
外科学 | 95篇 |
综合类 | 12篇 |
预防医学 | 39篇 |
眼科学 | 4篇 |
药学 | 29篇 |
肿瘤学 | 39篇 |
出版年
2023年 | 3篇 |
2022年 | 6篇 |
2021年 | 16篇 |
2020年 | 12篇 |
2019年 | 14篇 |
2018年 | 20篇 |
2017年 | 14篇 |
2016年 | 23篇 |
2015年 | 10篇 |
2014年 | 33篇 |
2013年 | 42篇 |
2012年 | 64篇 |
2011年 | 68篇 |
2010年 | 37篇 |
2009年 | 32篇 |
2008年 | 40篇 |
2007年 | 46篇 |
2006年 | 47篇 |
2005年 | 38篇 |
2004年 | 37篇 |
2003年 | 26篇 |
2002年 | 25篇 |
2001年 | 29篇 |
2000年 | 29篇 |
1999年 | 25篇 |
1998年 | 10篇 |
1997年 | 6篇 |
1996年 | 8篇 |
1995年 | 5篇 |
1994年 | 8篇 |
1993年 | 8篇 |
1992年 | 7篇 |
1991年 | 18篇 |
1990年 | 11篇 |
1989年 | 20篇 |
1988年 | 24篇 |
1987年 | 9篇 |
1986年 | 9篇 |
1985年 | 10篇 |
1984年 | 10篇 |
1983年 | 9篇 |
1982年 | 6篇 |
1980年 | 2篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 2篇 |
1976年 | 8篇 |
1975年 | 2篇 |
1967年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有945条查询结果,搜索用时 15 毫秒
941.
942.
Eleni I. Kampylafka Harry Alexopoulos Marinos C. Dalakas Athanasios G. Tzioufas 《Neurotherapeutics》2016,13(1):163-178
Neurological involvement is relatively common in the majority of systemic autoimmune diseases and may lead to severe morbidity and mortality, if not promptly treated. Treatment options vary greatly, depending on the underlying systemic pathophysiology and the associated neurological symptoms. Selecting the appropriate therapeutic scheme is further complicated by the lack of definite therapeutic guidelines, the necessity to differentiate primary neurological syndromes from those related to the underlying systemic disease, and to sort out adverse neurological manifestations caused by immunosuppressants or the biological agents used to treat the primary disease. Immunotherapy is a sine qua non for treating most, if not all, neurological conditions presenting in the context of systemic autoimmunity. Specific agents include classical immune modulators such as corticosteroids, cyclophosphamide, intravenous immunoglobulin, and plasma exchange, as well as numerous biological therapies, for example anti-tumor necrosis factor agents and monoclonal antibodies that target various immune pathways such as B cells, cytokines, and co-stimulatory molecules. However, experience regarding the use of these agents in neurological complications of systemic diseases is mainly empirical or based on small uncontrolled studies and case series. The aim of this review is to present the state-of-the-art therapies applied in various neurological manifestations encountered in the context of systemic autoimmune diseases; evaluate all treatment options on the basis of existing guidelines; and compliment these data with our personal experience derived from a large number of patients. 相似文献
943.
944.
Alex Alexopoulos MD PhD Maria Dakoutrou MD Msc Lamprini Nasi MD PhD Ioanna Thanopoulou MD Talia Kakourou MD PhD Louiza Kontara MD PhD Nikolaos Douladiris MD PhD Maria Galani MD Paraskevi Xepapadaki MD PhD Chrysoula Doxani MD PhD Theodoros Mprotsis PhD Elias Zintzaras PhD Nikolaos G. Papadopoulos MD PhD Christina Kanaka-Gantenbein MD PhD George P. Chrousos MD PhD 《Pediatric dermatology》2023,40(1):78-83
945.
【Objective】 To investigate effects of combined usage of dynamic neuro-electric stimulation(DNES) and M-cholynolytic therapy(oxybutynin) upon manifestations of neurogenic bladder dysfunctions(NBD) in children.【Method】 Urodynamics examination included registration of extemporaneous urinary excretion,urofluometry,and retrograde cytometry in horizontal and vertical position by example of urodynamic system(UDS) ACS 180 Plus(MENFIS BioMed.,USA).In accordance to severity of clinician manifestations,three groups of patients have been defined(27-highest one,49-middle and 51 low levels).Dynamic neuro-electrostimulation(DNES) procedures were conducted using the"DiaDNES-PKM"device(Russian Federation).The children were exposed to juxtaspinal stimulation on S1-S3 level-altogether 10 sessions have been performed.Oxybutynin(driptan) was used in dosage of 2.5 mg per diem.【Result】It was established that combined usage of DNES and oxybutynin in the group with highest severity caused the reduction of manifestations by 3.1 times while separately given DNES and basic therapy were followed by 34.1% and 28.0% reduction correspondently.Meanwhile,DNES and oxybutynin reduced severity in patients with pronounced disturbances by 7.5 times.Combined usage of oxybutynin and DNES in severely manifested NBD increased the effective volume of bladder by 2.3 times.Also significant reduction of both intrabladder pressure(by 48.0%) and compliance of the bladder(by 4.8 times) were detected under condition of combined usage of DNES and oxybutynin.All mentioned indices were modified to less extent in case of separate usage of DNES or oxybutynin when compared with the one registered after the combined their usage(P <0.05).【Conclusion】Combined usage of DENS and oxybutinin(driptan) is effective in most severe cases in children suffered from neurogenic overactive bladder. 相似文献